The addition of chemotherapy to hormonal therapy for treatment of patients with metastatic carcinoma of the prostate

R. P. Gibbons, S. Beckley, M. F. Brady, T. M. Chu, J. B. Dekernion, C. Dhabuwala, J. F. Gaeta, S. A. Loening, C. F. McKiel, D. G. McLeod, J. E. Pontes, G. R. Prout, P. T. Scardino, J. U. Schlegel, J. D. Schmidt, W. W. Scott, N. H. Slack, M. S. Soloway, G. P. Murphy

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Patients with advanced prostate carcinoma that had been stabilized by orchiectomy (ORCH) or hormone therapy for at least 3 months, were randomized to either diethylstilbestrol (DES) alone or DES plus Cytoxan or DES plus Emcyt. A total of 188 patients were randomized between July, 1976 and February, 1982 of which 161 were evaluable for objective response to treatment. Objective response rates, response duration, or survival experiences were not demonstrably different between treatment arms, either for all patients or within good or poor prognosis groups determined by initial pain or acid phosphatase level. Subjective improvements in performance status were small for each treatment. Pain relief was somewhat greater in the chemotherapy-hormone combinations than in the DES/ORCH, but the advantage was not statistically significant. Side effects were primarily nausea and vomiting and leukopenia, mostly in the DES + Cytoxan arm. The duration of stabilization prior to entry did not influence response overall, although there were opposing trends within each of the two chemotherapy arms. The premise for combining antitumor agents with hormones before hormone failure is still felt to be a more logical approach than waiting for the ultimate hormone failure, and a combination of hormones plus two antitumor agents is being evaluated in a subsequent ongoing trial where a more rigid design limits the duration of the preentry period of hormone stabilization.

Original languageEnglish
Pages (from-to)133-142
Number of pages10
JournalJournal of Surgical Oncology
Volume23
Issue number2
StatePublished - Aug 4 1983
Externally publishedYes

Fingerprint

Diethylstilbestrol
Prostate
Hormones
Carcinoma
Drug Therapy
Orchiectomy
Antineoplastic Agents
Cyclophosphamide
Therapeutics
Estramustine
Pain
Leukopenia
Acid Phosphatase
Combination Drug Therapy
Nausea
Vomiting
Survival

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Gibbons, R. P., Beckley, S., Brady, M. F., Chu, T. M., Dekernion, J. B., Dhabuwala, C., ... Murphy, G. P. (1983). The addition of chemotherapy to hormonal therapy for treatment of patients with metastatic carcinoma of the prostate. Journal of Surgical Oncology, 23(2), 133-142.

The addition of chemotherapy to hormonal therapy for treatment of patients with metastatic carcinoma of the prostate. / Gibbons, R. P.; Beckley, S.; Brady, M. F.; Chu, T. M.; Dekernion, J. B.; Dhabuwala, C.; Gaeta, J. F.; Loening, S. A.; McKiel, C. F.; McLeod, D. G.; Pontes, J. E.; Prout, G. R.; Scardino, P. T.; Schlegel, J. U.; Schmidt, J. D.; Scott, W. W.; Slack, N. H.; Soloway, M. S.; Murphy, G. P.

In: Journal of Surgical Oncology, Vol. 23, No. 2, 04.08.1983, p. 133-142.

Research output: Contribution to journalArticle

Gibbons, RP, Beckley, S, Brady, MF, Chu, TM, Dekernion, JB, Dhabuwala, C, Gaeta, JF, Loening, SA, McKiel, CF, McLeod, DG, Pontes, JE, Prout, GR, Scardino, PT, Schlegel, JU, Schmidt, JD, Scott, WW, Slack, NH, Soloway, MS & Murphy, GP 1983, 'The addition of chemotherapy to hormonal therapy for treatment of patients with metastatic carcinoma of the prostate', Journal of Surgical Oncology, vol. 23, no. 2, pp. 133-142.
Gibbons RP, Beckley S, Brady MF, Chu TM, Dekernion JB, Dhabuwala C et al. The addition of chemotherapy to hormonal therapy for treatment of patients with metastatic carcinoma of the prostate. Journal of Surgical Oncology. 1983 Aug 4;23(2):133-142.
Gibbons, R. P. ; Beckley, S. ; Brady, M. F. ; Chu, T. M. ; Dekernion, J. B. ; Dhabuwala, C. ; Gaeta, J. F. ; Loening, S. A. ; McKiel, C. F. ; McLeod, D. G. ; Pontes, J. E. ; Prout, G. R. ; Scardino, P. T. ; Schlegel, J. U. ; Schmidt, J. D. ; Scott, W. W. ; Slack, N. H. ; Soloway, M. S. ; Murphy, G. P. / The addition of chemotherapy to hormonal therapy for treatment of patients with metastatic carcinoma of the prostate. In: Journal of Surgical Oncology. 1983 ; Vol. 23, No. 2. pp. 133-142.
@article{9bdbff50adef4029be657c9acaf502e9,
title = "The addition of chemotherapy to hormonal therapy for treatment of patients with metastatic carcinoma of the prostate",
abstract = "Patients with advanced prostate carcinoma that had been stabilized by orchiectomy (ORCH) or hormone therapy for at least 3 months, were randomized to either diethylstilbestrol (DES) alone or DES plus Cytoxan or DES plus Emcyt. A total of 188 patients were randomized between July, 1976 and February, 1982 of which 161 were evaluable for objective response to treatment. Objective response rates, response duration, or survival experiences were not demonstrably different between treatment arms, either for all patients or within good or poor prognosis groups determined by initial pain or acid phosphatase level. Subjective improvements in performance status were small for each treatment. Pain relief was somewhat greater in the chemotherapy-hormone combinations than in the DES/ORCH, but the advantage was not statistically significant. Side effects were primarily nausea and vomiting and leukopenia, mostly in the DES + Cytoxan arm. The duration of stabilization prior to entry did not influence response overall, although there were opposing trends within each of the two chemotherapy arms. The premise for combining antitumor agents with hormones before hormone failure is still felt to be a more logical approach than waiting for the ultimate hormone failure, and a combination of hormones plus two antitumor agents is being evaluated in a subsequent ongoing trial where a more rigid design limits the duration of the preentry period of hormone stabilization.",
author = "Gibbons, {R. P.} and S. Beckley and Brady, {M. F.} and Chu, {T. M.} and Dekernion, {J. B.} and C. Dhabuwala and Gaeta, {J. F.} and Loening, {S. A.} and McKiel, {C. F.} and McLeod, {D. G.} and Pontes, {J. E.} and Prout, {G. R.} and Scardino, {P. T.} and Schlegel, {J. U.} and Schmidt, {J. D.} and Scott, {W. W.} and Slack, {N. H.} and Soloway, {M. S.} and Murphy, {G. P.}",
year = "1983",
month = "8",
day = "4",
language = "English",
volume = "23",
pages = "133--142",
journal = "Journal of Surgical Oncology",
issn = "0022-4790",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - The addition of chemotherapy to hormonal therapy for treatment of patients with metastatic carcinoma of the prostate

AU - Gibbons, R. P.

AU - Beckley, S.

AU - Brady, M. F.

AU - Chu, T. M.

AU - Dekernion, J. B.

AU - Dhabuwala, C.

AU - Gaeta, J. F.

AU - Loening, S. A.

AU - McKiel, C. F.

AU - McLeod, D. G.

AU - Pontes, J. E.

AU - Prout, G. R.

AU - Scardino, P. T.

AU - Schlegel, J. U.

AU - Schmidt, J. D.

AU - Scott, W. W.

AU - Slack, N. H.

AU - Soloway, M. S.

AU - Murphy, G. P.

PY - 1983/8/4

Y1 - 1983/8/4

N2 - Patients with advanced prostate carcinoma that had been stabilized by orchiectomy (ORCH) or hormone therapy for at least 3 months, were randomized to either diethylstilbestrol (DES) alone or DES plus Cytoxan or DES plus Emcyt. A total of 188 patients were randomized between July, 1976 and February, 1982 of which 161 were evaluable for objective response to treatment. Objective response rates, response duration, or survival experiences were not demonstrably different between treatment arms, either for all patients or within good or poor prognosis groups determined by initial pain or acid phosphatase level. Subjective improvements in performance status were small for each treatment. Pain relief was somewhat greater in the chemotherapy-hormone combinations than in the DES/ORCH, but the advantage was not statistically significant. Side effects were primarily nausea and vomiting and leukopenia, mostly in the DES + Cytoxan arm. The duration of stabilization prior to entry did not influence response overall, although there were opposing trends within each of the two chemotherapy arms. The premise for combining antitumor agents with hormones before hormone failure is still felt to be a more logical approach than waiting for the ultimate hormone failure, and a combination of hormones plus two antitumor agents is being evaluated in a subsequent ongoing trial where a more rigid design limits the duration of the preentry period of hormone stabilization.

AB - Patients with advanced prostate carcinoma that had been stabilized by orchiectomy (ORCH) or hormone therapy for at least 3 months, were randomized to either diethylstilbestrol (DES) alone or DES plus Cytoxan or DES plus Emcyt. A total of 188 patients were randomized between July, 1976 and February, 1982 of which 161 were evaluable for objective response to treatment. Objective response rates, response duration, or survival experiences were not demonstrably different between treatment arms, either for all patients or within good or poor prognosis groups determined by initial pain or acid phosphatase level. Subjective improvements in performance status were small for each treatment. Pain relief was somewhat greater in the chemotherapy-hormone combinations than in the DES/ORCH, but the advantage was not statistically significant. Side effects were primarily nausea and vomiting and leukopenia, mostly in the DES + Cytoxan arm. The duration of stabilization prior to entry did not influence response overall, although there were opposing trends within each of the two chemotherapy arms. The premise for combining antitumor agents with hormones before hormone failure is still felt to be a more logical approach than waiting for the ultimate hormone failure, and a combination of hormones plus two antitumor agents is being evaluated in a subsequent ongoing trial where a more rigid design limits the duration of the preentry period of hormone stabilization.

UR - http://www.scopus.com/inward/record.url?scp=0020578242&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020578242&partnerID=8YFLogxK

M3 - Article

C2 - 6343726

AN - SCOPUS:0020578242

VL - 23

SP - 133

EP - 142

JO - Journal of Surgical Oncology

JF - Journal of Surgical Oncology

SN - 0022-4790

IS - 2

ER -